Related Experiment Video
Updated: Jun 7, 2026
07:30
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Neurocognitive function in patients with β-thalassemia major
Ozgur Duman1, Sema Arayici, Cigil Fettahoglu
1Department of Pediatric Neurology, Akdeniz University, Antalya, Turkey.
Summary
Children with beta-thalassemia major (β-TM) exhibit cognitive impairments, including lower IQ scores and visuomotor dysfunction. Event-related potentials (ERP) may aid in early diagnosis of these cognitive deficits.
Area of Science:
- Pediatric Hematology
- Neuroscience
- Cognitive Psychology
Background:
- Beta-thalassemia major (β-TM) is associated with increased risk factors for cognitive impairment in children.
- Previous research indicates potential neurological complications in β-TM patients.
Purpose of the Study:
- To evaluate cognitive function in children diagnosed with β-TM.
- To compare cognitive performance and electrophysiological measures between β-TM patients and healthy controls.
Main Methods:
- A cohort of 20 children with β-TM was assessed alongside 21 healthy children.
- Neuropsychological tests and event-related potentials (ERP), including P300 and mismatch negativity, were utilized for evaluation.
Main Results:
- β-TM patients demonstrated significantly lower full-scale, performance, and verbal IQs compared to controls.
- Visuomotor dysfunction was more prevalent in the β-TM group.
- ERP analysis revealed prolonged latencies and reduced amplitudes in β-TM patients, indicating altered neural processing.
Conclusions:
- Neuropsychological tests are reliable for diagnosing cognitive impairment in β-TM.
- ERP measures show promise for facilitating early detection of cognitive deficits in β-TM.
- Larger patient cohorts are recommended for further investigation.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...